Archives
-
PVX Nucleoproteins as RNA Delivery Platforms
2026-10-13
Duoto and colleagues describe a proof-of-concept platform in which potato virus X nucleoprotein components assemble around mRNA or circular RNA. The study reports tunable particle architectures and reporter-protein expression in eukaryotic cells, but it does not establish therapeutic efficacy, in vivo performance, or clinical safety.
-
RBD-mRNA Shows Promise in MERS-CoV Mice
2026-10-13
A 2025 preclinical study directly compared MERS-CoV spike- and receptor-binding-domain mRNA vaccines. In mice, the RBD-focused vaccine produced stronger and more durable antibody responses, broader neutralization, and reported protection against viral challenge. The findings are encouraging but remain limited to an animal model and do not establish clinical efficacy or the role of any particular nucleotide reagent.
-
Lumiracoxib and COX-2 in Venom-Induced Muscle Injury
2026-10-12
A mouse study of Bothrops asper venom-induced skeletal-muscle injury reports a time-dependent role for the cyclooxygenase-2 pathway: COX-2 activity appeared protective during acute ischemia, whereas its inhibition was associated with later increases in angiogenic and matrix-remodeling markers. The findings are mechanistically informative but remain limited to a localized venom-injury model and do not establish a clinical treatment strategy.
-
N1-Methylpseudouridine and CRISPRa Evidence
2026-10-12
A source-grounded overview distinguishes the reported CRISPRa splice-diagnostics findings from supplier claims about N1-Methylpseudouridine, emphasizing evidence strength, provenance, and applicability limits.
-
Central Control of Opioid Mechanical Hypersensitivity
2026-10-10
A 2024 Neuron study identifies a lateral parabrachial–hypothalamic–spinal pathway that regulates morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. Its findings separate mechanical opioid side effects from better-established thermal mechanisms and provide a circuit-level framework for neuropharmacology opioid research.
-
Biotin-Tyramide: Product Overview and Evidence Limits
2026-10-09
Biotin-tyramide (SKU A8011) is described by APExBIO as a tyramide-based biotinylation reagent for conceptual use in enzyme-mediated signal amplification workflows such as immunohistochemistry (IHC) and in situ hybridization (ISH). No matched paper evidence was supplied, so performance and broader applicability cannot be independently assessed.
-
Lipid Nanoparticles for mRNA Delivery: Evidence and Limits
2026-10-09
This review examines how lipid composition, nanoparticle architecture, and manufacturing approaches shape nucleic-acid delivery, with emphasis on endosomal escape, biodistribution, immune interactions, and translational scalability. Its practical value lies in framing LNP performance as formulation-dependent while also identifying unresolved issues involving instability, off-target accumulation, immune activation, manufacturing, and regulation.
-
APOL1 Evolution, Isoforms, and APOL3
2026-10-08
Khalaila and Skorecki integrate population genetics, APOL1 splice-isoform biology, and APOL1–APOL3 interaction data to refine explanations for APOL1-associated cellular injury. The study argues that renal-risk mechanisms cannot be understood from G1 and G2 coding changes alone, because haplotype context, isoform identity, and interactions with other APOL proteins may all influence cellular behavior.
-
Cas9 mRNA in TBI Research: Evidence and Limits
2026-10-08
A source-grounded overview of ZIPK biology after traumatic brain injury and the conceptual role, evidence boundaries, and limitations of EZ Cap™ Cas9 mRNA (m1Ψ) in future CRISPR-Cas9 genome editing research.
-
EGFP mRNA m1Ψ in Delivery Research
2026-10-07
EGFP mRNA m1Ψ is best understood as a reporter platform for studying RNA delivery and protein expression, not as evidence of therapeutic performance by itself. This overview places N1-methylpseudouridine EGFP mRNA in the context of a 2026 Klotho mRNA study, comparing what the findings support, what remains uncertain, and where applicability boundaries matter.
-
N1-Methylpseudo-UTP: Evidence and Applications
2026-10-07
N1-Methyl-Pseudouridine-5'-Triphosphate, also called N1-Methylpseudo-UTP, is a modified nucleoside triphosphate used in research on synthetic RNA. Evidence from a 2022 Cell Reports study indicates that N1-methylpseudouridine can support accurate translation without substantially increasing miscoding in the tested systems. However, these findings do not establish universal gains in RNA stability, immunological performance, clinical efficacy, or safety.
-
CTOP and Opioid Mechanical Hypersensitivity
2026-10-06
A source-grounded overview of CTOP as a μ-opioid receptor antagonist and its conceptual relevance to recent research on opioid-induced mechanical hypersensitivity and analgesic tolerance. The discussion separates supplier-reported product information from findings in a 2024 mouse study and emphasizes evidence strength, unresolved mechanisms, and limits on translation to human pain care.
-
5-Methoxy-UTP in RNA-LNP Research: Evidence Review
2026-10-06
The available evidence supports a broader role for machine learning in lipid nanoparticle formulation research, but it does not establish a direct application or performance profile for 5-Methoxy-UTP. This overview separates the published findings from the product listing, evaluates evidence strength, and defines the main applicability limits.
-
Perospirone: Receptor Pharmacology and Kv1.5 Evidence
2026-10-05
Perospirone, also called SM-9018 free base, combines reported 5-HT2A and D2 receptor antagonism with 5-HT1A partial agonism. A 2025 cellular study additionally reported concentration-dependent inhibition of vascular Kv currents, supporting a research hypothesis about neurovascular pharmacology rather than proving a clinical cardiovascular effect.
-
CRISPRa for Splice-Altering Variants in Fibroblasts
2026-10-05
Terkelsen and colleagues developed a CRISPR activation strategy that induces expression of otherwise inaccessible disease genes in patient-derived skin fibroblasts. The study shows how this approach can support transcript-level analysis of splice-altering variants in MPZ and SPAST, while also defining important boundaries for diagnostic interpretation.